Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT Stock Report

Market Cap: US$572.3m

Phathom Pharmaceuticals Management

Management criteria checks 3/4

Phathom Pharmaceuticals' CEO is Terrie Curran, appointed in Dec 2019, has a tenure of 5.33 years. total yearly compensation is $3.41M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $1.42M. The average tenure of the management team and the board of directors is 5 years and 5.1 years respectively.

Key information

Terrie Curran

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage20.2%
CEO tenure5yrs
CEO ownership0.2%
Management average tenure5yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Dec 11

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 18

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Aug 02

The Prognosis For Phathom Pharmaceuticals

Jun 22

Phathom Pharmaceuticals: Undiscovered Gem

Jan 20

Phathom Pharma prices equity offering at $42

Dec 17

Phathom Pharma launches equity offering

Dec 15

Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder

Nov 30

CEO Compensation Analysis

How has Terrie Curran's remuneration changed compared to Phathom Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$339m

Jun 30 2024n/an/a

-US$297m

Mar 31 2024n/an/a

-US$247m

Dec 31 2023US$3mUS$688k

-US$202m

Sep 30 2023n/an/a

-US$177m

Jun 30 2023n/an/a

-US$185m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$5mUS$650k

-US$198m

Sep 30 2022n/an/a

-US$179m

Jun 30 2022n/an/a

-US$164m

Mar 31 2022n/an/a

-US$150m

Dec 31 2021US$6mUS$568k

-US$144m

Sep 30 2021n/an/a

-US$162m

Jun 30 2021n/an/a

-US$159m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$5mUS$499k

-US$129m

Sep 30 2020n/an/a

-US$173m

Jun 30 2020n/an/a

-US$207m

Mar 31 2020n/an/a

-US$274m

Dec 31 2019US$4mUS$42k

-US$255m

Compensation vs Market: Terrie's total compensation ($USD3.41M) is above average for companies of similar size in the US market ($USD2.09M).

Compensation vs Earnings: Terrie's compensation has been consistent with company performance over the past year.

CEO

Terrie Curran (55 yo)

5yrs

Tenure

US$3,411,022

Compensation

Ms. Terrie J. Curran is a Director of Phathom Pharmaceuticals, Inc. since August 2019 and serves as its Chief Executive Officer since December 02, 2019 and also serves as its President. Ms. Curran serves a...

Leadership Team

NamePositionTenureCompensationOwnership
Terrie Curran
President5yrsUS$3.41m0.25%
$ 1.4m
David Socks
Co-Founder & Directorno dataUS$266.34k1.79%
$ 10.2m
Azmi Nabulsi
Co-Founder & COO5.8yrsUS$2.04m1.33%
$ 7.6m
Molly Henderson
Chief Financial & Business Officer2.7yrsUS$1.87m0.071%
$ 406.2k
Aditya Kohli
Co-Founderno dataUS$319.65kno data
Paul Cocja
Chief People Officerless than a yearno datano data
Tom Harris
Chief Development Sciences Officerno datano datano data
Eckhard Leifke
Chief Medical Officer5yrsno datano data
Martin Gilligan
Chief Commercial Officer4.9yrsno datano data

5.0yrs

Average Tenure

53yo

Average Age

Experienced Management: PHAT's management team is considered experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Terrie Curran
President5.3yrsUS$3.41m0.25%
$ 1.4m
David Socks
Co-Founder & Director6.9yrsUS$266.34k1.79%
$ 10.2m
Michael Cola
Independent chairman of the Board5.3yrsUS$331.34k0.027%
$ 157.3k
Heidi Fields
Independent Director5.3yrsUS$287.17k0.013%
$ 75.3k
James Topper
Independent Director2.3yrsUS$267.14k0.032%
$ 180.7k
Frank Karbe
Independent Director2.7yrsUS$283.84k0.050%
$ 284.6k
Asit Parikh
Independent Director5yrsUS$279.67k0.080%
$ 460.4k
Mark Stenhouse
Independent Director4.8yrsUS$283.84k0.013%
$ 75.3k

5.1yrs

Average Tenure

56.5yo

Average Age

Experienced Board: PHAT's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 22:50
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Phathom Pharmaceuticals, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC
Umer RaffatEvercore ISI